-
1Academic Journal
Source: Патология кровообращения и кардиохирургия, Vol 28, Iss 3 (2024)
-
2Academic Journal
Authors: Tseluyko, V.Y., Yakovleva, L.M., Sukhova, S.M.
Source: EMERGENCY MEDICINE; № 6.77 (2016); 102-110
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; № 6.77 (2016); 102-110
МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; № 6.77 (2016); 102-110Subject Terms: 2. Zero hunger, 03 medical and health sciences, тромбоемболія легеневих артерій, гендерні особливості, короткостроковий прогноз, 0302 clinical medicine, pulmonary embolism, gender characteristics, short-term prognosis, тромбоэмболия легочных артерий, гендерные особенности, краткосрочный прогноз, 3. Good health
File Description: application/pdf
-
3Academic Journal
Authors: Maiborodin I.V., Ryaguzov M.E., Kuzkin S.A., Shevela A.A., Sheplev B.V., Marinkin I.O., Maiborodina V.I., Lushnikova E.L.
Contributors: 0
Source: Traumatology and Orthopedics of Russia; Vol 30, No 2 (2024); 131-142 ; Травматология и ортопедия России; Vol 30, No 2 (2024); 131-142 ; 2542-0933 ; 2311-2905 ; 10.17816/2311-2905-2024-30-2
Subject Terms: intraosseous implantation metallic devices, extracellular vesicles derived from mesenchymal stromal cells, thrombosis, cardiac thromboembolism, pulmonary thromboembolism, внутрикостная имплантация, экстрацеллюлярные везикулы мезенхимных стромальных клеток, тромбоз, тромбоэмболия сердца, тромбоэмболия легочных артерий
File Description: application/pdf
Relation: https://journal.rniito.org/jour/article/view/17519/pdf; https://journal.rniito.org/jour/article/downloadSuppFile/17519/150577; https://journal.rniito.org/jour/article/downloadSuppFile/17519/150578; https://journal.rniito.org/jour/article/downloadSuppFile/17519/150579; https://journal.rniito.org/jour/article/downloadSuppFile/17519/150924; https://journal.rniito.org/jour/article/downloadSuppFile/17519/150925; https://journal.rniito.org/jour/article/downloadSuppFile/17519/150926; https://journal.rniito.org/jour/article/view/17519
-
4Academic Journal
Authors: Евгения Александровна Шмидт, Ирина Игоревна Жидкова, Татьяна Юрьевна Пенская, Ольга Леонидовна Барбараш
Source: Медицина в Кузбассе, Vol 21, Iss 4, Pp 108-115 (2022)
Subject Terms: тромбоэмболия легочных артерий, рецидив тромбоэмболии, тромбодинамика, Medicine
File Description: electronic resource
-
5Academic Journal
Authors: I. S. Yavelov, И. С. Явелов
Contributors: The work was carried out within the framework of the state task “The choice of the optimal method for the treatment of acute ascending varicothrombophlebitis of the veins of the lower extremities: comparison of the results of endovenous laser obliteration of the great saphenous vein and conservative therapy”, registration No. 121021100116-2., Работа выполнена в рамках государственного задания «Выбор оптимального способа лечения острого восходящего варикотромбофлебита вен нижних конечностей: сопоставление результатов эндовенозной лазерной облитерации большой подкожной вены и консервативной терапии», регистрационный №121021100116-2.
Source: Aterotromboz = Atherothrombosis; Том 12, № 2 (2022); 22-31 ; Атеротромбоз; Том 12, № 2 (2022); 22-31 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2022-2
Subject Terms: тромбоз глубоких вен, тромбоэмболия легочных артерий, D-димер, антикоагулянты, апиксабан, pulmonary embolism, D-dimer, anticoagulants, apixaban
File Description: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/284/297; Бокерия Л.А., Затевахин И.И., Кириенко А.И., Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;9(4-2):1–51. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/pe2015.pdf.; Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.J., Harjola V.P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.; Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. https://doi.org/10.1182/bloodadvances.2020001830.; Stevens S.M., Woller S.C., Kreuziger L.B., Bounameaux H., Doerschug K., Geersing G.J. et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021; 160(6):e545–e608. https://doi.org/10.1016/j.chest.2021.07.055.; Mazzolai L., Ageno W., Alatri A., Bauersachs R., Becattini C., Brodmann M. et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol. 2022;29(8):1248–1263. https://doi.org/10.1093/eurjpc/zwab088.; Kakkos S.K., Gohel M., Baekgaard N., Bauersachs R., Bellmunt-Montoya S., Black S.A. et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9–82. https://doi.org/10.1016/j.ejvs.2020.09.023.; Prins M.H., Lensing A.W.A., Prandoni P., Wells P.S., Verhamme P., Beyer-Westendorf J. et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018;2(7):788–796. https://doi.org/10.1182/bloodadvances.2018017160.; Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A. et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780–1789. https://doi.org/10.1056/NEJMoa054444.; Cosmi B., Legnani C., Tosetto A., Pengo V., Ghirarduzzi A., Testa S. et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood. 2010;115(3):481–488. https://doi.org/10.1182/blood-2009-08-237354.; Rodger M.A., Le Gal G., Anderson D.R., Schmidt J., Pernod G., Kahn S.R. et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065. https://doi.org/10.1136/bmj.j1065.; Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. https://doi.org/10.1056/NEJMoa1207541.; Palareti G., Poli D., Ageno W., Legnani C., Antonucci E., Bucherini E. et al. D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. Blood Adv. 2022:bloodadvances.2022007973. https://doi.org/10.1182/bloodadvances.2022007973.; Стойко Ю.М., Кириенко А.И., Илюхин Е.А., Лобастов К.В., Чаббаров Р.Г., Париков М.А. и др. Диагностика и лечение тромбофлебита поверхностных вен конечностей. Рекомендации Ассоциации флебологов России. Флебология. 2019;13(2):78–97. https://doi.org/10.17116/flebo20191302178.; Decousus H., Prandoni P., Mismetti P., Bauersachs R.M., Boda Z., Brenner B. et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med. 2010;363(13):1222–1232. https://doi.org/10.1056/NEJMoa0912072.; Cosmi B., Filippini M., Tonti D., Avruscio G., Ghirarduzzi A., Bucherini E. et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost. 2012;10(6):1026–1235. https://doi.org/10.1111/j.1538-7836.2012.04727.x.; Beyer-Westendorf J., Schellong S.M., Gerlach H., Rabe E., Weitz J.I., Jersemann K. et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017;4(3):e105–e113. https://doi.org/10.1016/S2352-3026(17)30014-5.; https://www.aterotromboz.ru/jour/article/view/284
-
6Academic Journal
Source: Медицина в Кузбассе, Vol 21, Iss 4, Pp 108-115 (2022)
Subject Terms: рецидив тромбоэмболии, тромбодинамика, тромбоэмболия легочных артерий, Medicine
-
7Academic Journal
Authors: Шмидт, Евгения Александровна, Жидкова, Ирина Игоревна, Пенская, Татьяна Юрьевна, Барбараш, Ольга Леонидовна
Source: Medicine in Kuzbass; Том 21, № 4 (2022): декабрь; 108-115 ; Медицина в Кузбассе; Том 21, № 4 (2022): декабрь; 108-115 ; 2588-0411 ; 1819-0901
Subject Terms: pulmonary embolism, recurrence of thromboembolism, thrombodynamics, тромбоэмболия легочных артерий, рецидив тромбоэмболии, тромбодинамика
File Description: text/html; application/pdf
Relation: http://mednauki.ru/index.php/MK/article/view/821/1464; http://mednauki.ru/index.php/MK/article/view/821/1486; http://mednauki.ru/index.php/MK/article/downloadSuppFile/821/1078; http://mednauki.ru/index.php/MK/article/downloadSuppFile/821/1079; http://mednauki.ru/index.php/MK/article/downloadSuppFile/821/1080; http://mednauki.ru/index.php/MK/article/view/821
Availability: http://mednauki.ru/index.php/MK/article/view/821
-
8Academic Journal
Authors: I. Yavelov S., И. Явелов С.
Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 6 (2021); 908-915 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 6 (2021); 908-915 ; 2225-3653 ; 1819-6446
Subject Terms: COVID-19, venous thromboembolism, deep vein thrombosis, pulmonary embolism, prevention, heparin, enoxaparin, direct oral anticoagulants, rivaroxaban, apixaban, betrixaban, новая коронавирусная инфекция, венозные тромбоэмболические осложнения, тромбоз глубоких вен, тромбоэмболия легочных артерий, профилактика, гепарин, эноксапарин, прямые оральные антикоагулянты, ривароксабан, апиксабан, бетриксабан
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2620/2251; Leentjens J, van Haaps TF, Wessels PF, et al. COVID-19-associated coagulopathy and an-tithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524-e533. DOI:10.1016/S2352-3026(21)00105-8.; Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19(4):1064-1070. DOI:10.1111/jth.15267.; Patell R, Bogue T, Koshy A, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342-6. DOI:10.1182/blood.2020007938.; Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism follow-ing hospital admission with COVID-19. Blood. 2020;136(11):1347-50. DOI:10.1182/blood.2020008086.; Bourguignon A, Beaulieu C, Belkaid W, et al. Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection. Thromb Res. 2020;196:491-3. DOI:10.1016/j.thromres.2020.10.017.; Salisbury R, Iotchkova V, Jaafar S, et al. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Avd. 2020;4(24):6230-9. DOI:10.1182/bloodadvances.2020003349.; Roubinian NH, Dusendang JR, Mark DG, et al. Incidence of 30-Day Venous Thromboembo-lism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. JAMA Intern Med. 2021;181(7):997-1000. DOI:10.1001/jamainternmed.2021.0488.; Giannis D, Allen SL, Tsang J, et al., behalf of the Northwell COVID-19 Research Consorti-um. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838-47. DOI:10.1182/blood.2020010529.; Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis. 2006;22(1):31-8. DOI:10.1007/s11239-006-7732-5.; Hull RD, Schellong SM, Tapson VF, et al., EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8-18. DOI:10.7326/0003-4819-153-1-201007060-00004.; Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-77. DOI:10.1056/NEJMoa1110899.; Cohen AT, Spiro TE, Büller HR, et al., MAGELLAN Investigators. Rivaroxaban for throm-boprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-23. DOI:10.1056/NEJ-Moa1111096.; Cohen AT, Harrington RA, Goldhaber SZ, et al., for the APEX Investigators. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016;375(6):534-44. DOI:10.1056/NEJMoa1601747.; Spyropoulos AC, Ageno W, Albers GW, et al., for the MARINER Investigators. Rivaroxa-ban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018;379(12):1118-27. DOI:10.1056/NEJMoa1805090.; Spyropoulos AC, Ageno W, Albers GW, et al. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. JACC. 2020;75(25):3140-7. DOI:10.1016/j.jacc.2020.04.071.; XARELTO (rivaroxaban) tablets, for oral use. Highlights of prescribing information [cited 2021 Nov 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf.; Ribeiro MS, Dusilek C, Itinose K, et al., on behalf of the MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. 2021 Dec 15;S0140-6736(21)02392-8. doi:10.1016/S0140-6736(21)02392-8.; Ramacciotti E, Agati LB, Calderaro D, et al. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. Am Heart J. 2021;242:115-22. DOI:10.1016/j.ahj.2021.08.016.; https://www.rpcardio.com/jour/article/view/2620
-
9Academic Journal
Authors: S.V. Anikin, V.V. Yanovoy, S.V. Khodus
Source: Yakut Medical Journal. :34-36
Subject Terms: 2. Zero hunger, тромбоэмболические осложнения, stratification, колоректальный рак, стратификация, тромбоэмболия легочных артерий, colorectal cancer, thromboembolic complications, thromboembolism of the pulmonary artery, 3. Good health
-
10Academic Journal
Source: Патология кровообращения и кардиохирургия, Vol 16, Iss 1, Pp 47-49 (2018)
Subject Terms: ТРОМБОЗ, ОСТРАЯ ТРОМБОЭМБОЛИЯ ЛЕГОЧНЫХ АРТЕРИЙ, ТРОМБОФИЛИЯ, Surgery, RD1-811
File Description: electronic resource
-
11Academic Journal
Authors: Igor S. Yavelov, И. С. Явелов
Contributors: статья подготовлена при финансовой поддержке компании «Пфайзер».
Source: Aterotromboz = Atherothrombosis; № 2 (2018); 54-67 ; Атеротромбоз; № 2 (2018); 54-67 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2018-2
Subject Terms: варфарин, deep vein thrombosis, pulmonary artery thromboembolism, bleeding, apixaban, warfarin, тромбоз глубоких вен, тромбоэмболия легочных артерий, кровотечения, апиксабан
File Description: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/166/198; Kirchhof P., BenusSi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The task Force for the management of atrial fibrillation of the european society of Cardiology (ESC). Developed with the special contribution of the european Heart Rhythm Association (EHRA) of the ESC. endorsed by the european stroke organisation (ESO). Eur Heart J. 2016; 50: e1-e88.; Steffel J., Verhamme P., Potpara T.S., et al. The 2018 european Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2018; 39: 1330-1393.; Konstantinides S., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. the task Force for the Diagnosis and Management of Acute Pulmonary embolism of the european society of Cardiology (ESC). endorsed by the european Respiratory society (ERS). Eur Heart J. 2014; 35: 3033-3069.; Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE Disease. Chest Guideline and expert Panel Report. Chest. 2016; 149: 315-352.; Hsu J.C., Maddox T.M., Kennedy K.F., et al. Oral Anticoagulant therapy Prescription in Patients with Atrial Fibrillation Across the spectrum of stroke Risk Insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016; 1: 55-62.; Степина Е.В., Лукьянов М.М., Бичурина М.А., Белова Е.Н., Кудряшов Е.В., Юзьков Ю.В., Бойцов С.А. Терапия оральными антикоагулянтами у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью на госпитальном и амбулаторном этапах лечения по данным регистра РЕКВАЗА-КЛИНИКА. Рациональная фармакотерапия в кардиологии. 2017; 13(2):146-154. [Stepina E.V., Lukyanov M.M., Bichurina M.A., Belova E.N., Kudryashov E.V., Yuzkov Yu.V., Boytsov S.A. Therapy with oral anticoagulants in patients with atrial fibrillation in combination with arterial hypertension, ischemic heart disease, chronic heart failure in the hospital and outpatient stages of treatment according to the REQUESIS CLINIC register. Rational pharmacotherapy in cardiology. 2017; 13 (2): 146-154.]; Бойцов С.А., Марцевич С.Ю., Кутишенко Н.П., Лукьянов М.М., и соавт. Исследование «РЕГИстр больных, перенесших Острое Нарушение мозгового кровообращения (РЕГИОН)». Часть 1. Госпитальный проспективный регистр больных, перенесших острое нарушение мозгового кровообращения (по результатам пилотного этапа исследования). Рациональная фармакотерапия в кардиологии. 2016; 12(6): 645-653. [Boytsov S.A., Martsevich S.Yu., Kutishenko N.P., Lukyanov M.M., et al. The study “Register of patients who had Acute Cerebrovascular disease (REGION)”. Part 1. Hospital prospective register of patients who had acute cerebral circulation (according to the results of the pilot phase of the study). Rational pharmacotherapy in cardiology. 2016; 12 (6): 645-653.]; Haas S., Ten Cate H., Accetta G., et al.; GARFIELD-AF Investigators. Quality of Vitamin K Antagonist Control and 1-Year outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One. 2016; 11: e0164076.; Гайсенок О.В., Леонов А.С. Применение пероральных антикоагулянтов у пациентов с фибрилляцией предсердий: данные когортного исследования. Рациональная фармакотерапия в кардиологии. 2016;12: 376-379. [Gaisenok O.V., Leonov A.S. The use of oral anticoagulants in patients with atrial fibrillation: cohort data. rational pharmacotherapy in cardiology. 2016; 12: 376-379.]; Granger C.B., Alexander J.H., McMurray J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992.; Hylek e.M., Held C., Alexander J.H., et al. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin in the ARISTOTLE trial: Predictors, Characteristics, and Clinical outcomes. JACC. 2014; 63: 2141-2147.; Lopes R.D., Al-Khatib S.M., Wallentin L., et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012; 380: 1749-1758.; Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012; 33: 2821-2830.; Wallentin L., Lopes R.D., Hanna M., et al. Efficacy and safety of apixaban compared with warfarin in different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation. 2013: 127: 2166-2176.; Halvorsen S., Atar D., Yang H., et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014; 35:1864-1872.; Alexander J.H., Andersson U., Lopes R.D., et al.; For the Apixaban for Reduction of stroke and other thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5mg twice Daily and Clinical outcomes in Patients With Atrial Fibrillation and Advanced Age, LowBodyWeight, or High Creatinine. A secondary Analysis of a Randomized Clinical trial. JAMA Cardiol. 2016; 1: 673-681.; Rao M.P., Vinereanu D., Wojdyla D.M., et al. Clinical outcomes and History of Fall in Patients with Atrial Fibrillation treated with oral Anticoagulation: Insights from the ARISTOTLE trial. Am J Med. 2018; 131: 269-275.; De Caterina R., Andersson U., Alexander J.H., et al.; ARISTOTLE Investigators. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in stroke and other thromboembolic events in Atrial Fibrillation trial. Am Heart J. 2016: 175-183.; Lanas F., Xavier D., Husted s., et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016; 353: i2868.; Flaker G., Lopes R.D., Hylek e., et al.; ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. JACC. 2014; 64: 1541-1550.; Alexander J.H., Lopes R.D., Thomas L., et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014; 35: 224-232.; Bahit M.C., Lopes R.D., Wojdyla D.M., et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013; 170: 215-220.; Hu P.T., Lopes R.D., Stevens S.R., et al. Efficacy and safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE trial. J Am Heart Assoc. 2017 Jan 17;6(1). pii: e004699. doi:10.1161/JAHA.116.004699.; Agnelli G., Buller H.R., Cohen A., et al., For the AMPLIFY Investigators. oral Apixaban for the treatment of Acute Venous thromboembolism. N Engl J Med. 2013; 369: 799-808.; Raskob G.E., Gallus A.S., Sanders P., et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016; 115: 809-816.; Sharma M., Cornelius V.R., Patel J.P., et al. Efficacy and Harms of Direct oral Anticoagulants in the elderly for stroke Prevention in Atrial Fibrillation and secondary Prevention of Venous thromboembolism: systematic Review and Meta-Analysis. Circulation. 2015; 132: 194-204.; Li X., DeitelzweIg S., Keshishian A., et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “realworld” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017. doi:10.1160/tH17-01-0068.; https://www.aterotromboz.ru/jour/article/view/166
-
12Academic Journal
Authors: I. S. Yavelov
Source: Атеротромбоз, Vol 0, Iss 2, Pp 32-38 (2015)
Subject Terms: тромбоз глубоких вен, тромбоэмболия легочных артерий, пероральные антикоагулянты, апиксабан, Internal medicine, RC31-1245
File Description: electronic resource
-
13Academic Journal
Authors: MV Avksentyeva, OV Shatalova
Source: Медицинский совет, Vol 0, Iss 8, Pp 18-23 (2014)
Subject Terms: анализ минимизации затрат, тромбоз глубоких вен (тгв), тромбоэмболия легочных артерий (тэла), ривароксабан, эноксапарин, варфарин, cost reduction evaluation, deep vein thrombosis (dvt), pulmonary thromboembolism (pte), rivaroxaban, enoxaparin, warfarin, Medicine
File Description: electronic resource
-
14Academic Journal
Authors: A. A. Yatsenko, T. I. Petrenko, P. N. Filimonov
Source: Туберкулез и болезни лёгких, Vol 95, Iss 8, Pp 35-40 (2017)
Subject Terms: туберкулез, тромбоэмболия легочных артерий, тромбоз глубоких вен, легочная хирургия, тест тромбодинамики, тромбоэластометрия, центральный венозный катетер, генетические полиморфизмы, Diseases of the respiratory system, RC705-779
Relation: https://www.tibl-journal.com/jour/article/view/1032; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506; https://doaj.org/article/b55c9c731db64d7dae02ea1b56c866c1
-
15Academic Journal
Authors: Bablyak, S. D., Rudyk, Yu. S., Faynyk, A. F.
Source: Ukrainian Therapeutical Journal; № 1 (2018); 64—71
Украинский терапевтический журнал; № 1 (2018); 64—71
Український терапевтичний журнал; № 1 (2018); 64—71Subject Terms: pulmonary embolism, risk scales, dabigatran, warfarin, тромбоэмболия легочных артерий, шкалы риска, дабигатран, варфарин, 3. Good health, тромбоемболія легеневих артерій, шкали ризику, дабігатран
File Description: application/pdf
Access URL: http://utj.com.ua/article/view/128456
-
16Academic Journal
Authors: МЕДВЕДЕВ А.П., НЕМИРОВА С.В., ХУБУЛАВА Г.Г., ДЕМАРИН О.И., ДЕРЯБИН Р.А., ЖУРКО С.А., ПИЧУГИН В.В.
Subject Terms: ТРОМБОЭМБОЛИЯ ЛЕГОЧНЫХ АРТЕРИЙ,ЛЕЧЕНИЕ ТЭЛА,ИСХОДЫ ТЭЛА
File Description: text/html
-
17Academic Journal
Authors: РЯБИНКИНА Ю.В., ПИРАДОВ М.А., ТАНАШЯН М.М., ШАБАЛИНА А.А., КОСТЫРЕВА М.В.
File Description: text/html
-
18Academic Journal
Authors: A. N. Shilova, A. A. Karpenko, N. A. Karmadonova, M. V. Starosotskaya, А. Н. Шилова, А. А. Карпенко, Н. А. Кармадонова, М. В. Старосоцкая
Source: Complex Issues of Cardiovascular Diseases; № 1 (2012); 40-42 ; Комплексные проблемы сердечно-сосудистых заболеваний; № 1 (2012); 40-42 ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2017-0-2
Subject Terms: гематогенные тромбофилии, acute pulmonary embolism, hematogenic thrombophilia, hematogenous thrombophilias, острая тромбоэмболия лёгочных артерий
File Description: application/pdf
Relation: https://www.nii-kpssz.com/jour/article/view/94/97; Баркаган З. С. Клинико-диагностические варианты, номенклатура и основы диагностики гематогенных тромбофилий // Проблемы гематологии и переливания крови. 1996. № 3. С. 5–15.; Баркаган З. С., Костюченко Г. И., Котовщикова Е. Ф. Гипергомоцистеинемия как самостоятельный фактор риска поражения и тромбирования кровеносных сосудов // Патология кровообращения и кардиохирургия. 2002. № 1. С. 65–71.; Воробьев А. И. Руководство по гематологии. М.: Ньюдиамед, 2005. Т. 3. 467 с.; Bauer K. A. Management of thrombophilia // J. Thrombos. Haemost. 2003. Vol. 1, № 7. P. 1429–1434.; Greaves M. Antiphospholipid antibodies and thrombosis // Lancet. 1999. Vol. 353. С. 1348–1353.; Heit J. A. The epidemiology of venous thromboembolism in the community // Arterioscler. Thromb. Vasc Biol. 2008. Mar. Vol. 28(3). Р. 370–372.; High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism / R. A. Kraaÿenhagen, P. S. Anker, M. M. Koopman et al. // Thromb. Haemost. 2000. Vol. 83. Р. 5–9.; Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis // N. Engl. J. Med. 1994. Vol. 330. Р. 517–522
-
19Academic Journal
Authors: НЕМИРОВА СВЕТЛАНА ВЛАДИМИРОВНА, КАЦУБО ЛЮДМИЛА БОРИСОВНА, КРИНИНА ИННА ВЛАДИМИРОВНА, КОЗИНА МАРИНА БОРИСОВНА, МЕДВЕДЕВ АЛЕКСАНДР ПАВЛОВИЧ, РЫБИНСКИЙ АЛЕКСЕЙ ДМИТРИЕВИЧ, ЦЕЛОУСОВА ЛАДА МАКСИМОВНА
File Description: text/html
-
20Academic Journal
Authors: Шилова, Анна, Карпенко, А., Клеванец, Ю., Кармадонова, Н.
Subject Terms: ТРОМБОЭМБОЛИЯ ЛЕГОЧНЫХ АРТЕРИЙ, ОНКОЛОГИЯ, ТРОМБОФИЛИЯ
File Description: text/html
